Arena Pharmaceuticals presents clinician and patient reported outcomes data from phase 2b ADVISE trial evaluating etrasimod in adult atopic dermatitis during a late-breaking session at American Academy of Dermatology VMX
(LaVoieHealthScience) Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced data at a late-breaking session at the American Academy of Dermatology VMX Experience. Etrasimod, a novel investigational drug candidate to treat moderate-to-severe atopic dermatitis (AD), demonstrated statistical significance in both clinician and patient reported outcomes in the ADVISE Phase 2b clinical trial.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Academies | Clinical Trials | Dermatitis | Dermatology | International Medicine & Public Health | Skin | Statistics